← Evidence map

ArticleVaccine: X2023

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18-55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial.

Akram Ansarifar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18-55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial. | OpenQuestion